Skip to main content
SpringerLink
Log in

The Clinical Thrombosis Center and Clinical Thrombologist: A New US Health Systems Paradigm for the Management of Venous Thromboembolic Disease

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

New paradigms for the diagnosis, prophylaxis, acute treatment, and ongoing management of patients with venous thromboembolic disease (VTE), a better understanding of the genotypic and phenotypic mechanisms of thrombophilic states, and the possibility of a greatly expanded armamentarium of antithrombotic therapies are necessitating a more formalized and systematic approach to VTE management. This has required many US healthcare institutions to develop piecemeal approaches in management models for VTE utilizing local champions from a variety of subspecialties. Development of a formalized Clinical Thrombosis Center from an already established Anticoagulant Management Service utilizing a clinical thrombologist, a new role for a physician who has developed expertise in anticoagulation and VTE management, presents a new paradigm in which this disease may be approached at a formalized, institutional level. Thus the clinical thrombologist working through a Clinical Thrombosis Center can develop a system-of-care approach to link the rapid advances in the field of thromboembolism to clinical applications, formulate evidence-based disease management guidelines, and conduct patient-oriented translational clinical research in VTE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Perrier A, Desmarais S, Miron M-J, et al. Non-invasive diagnosis of venous thromboembolism in outpatients.Lancet 1999;353:190-195.

    Google Scholar 

  2. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998;129:997-1005.

    Google Scholar 

  3. Anderson DR, Wells PS, Stiell I, et al. Thrombosis in the emergency department: Use of a clinical diagnosis model to safely avoid the need for urgent radiological investigation.Arch Intern Med 1999;159:477-482.

    Google Scholar 

  4. Swensen SJ, Sheedy PF II, Ryu JH, et al. Outcomes after withholding anticoagulation from patients with suspected acute pulmonary embolism and negative computed tomographic findings: A cohort study. Mayo Clin Proc 2002;77:130-138.

    Google Scholar 

  5. Rathbun SW, Raskob GE, Whitsett TL, et al. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: A systematic review.Ann Intern Med 2000;132:227-232.

    Google Scholar 

  6. Fraser DGW, Moody AR, Morgan PS, et al. Diagnosis of lower-limb deep venous thrombosis: A prospective blinded study of magnetic resonance direct thrombus imaging. Ann Intern Med 2002;136:89-98.

    Google Scholar 

  7. Samama MM, Cohen AT, Darmon J-Y, et al. Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.

    Google Scholar 

  8. Eikelboom JW, Quinlan DJ, Douketis JD. Extendedduration prophylaxis against venous thromboembolism after total hip or knee replacement: A metaanalysis of the randomised trials. Lancet 2001;358:9-15.

    Google Scholar 

  9. Hull RD, Pineo GF, Stein PD, et al. Extended outof-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A systematic review. Ann Intern Med 2001;135:858-869.

    Google Scholar 

  10. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346: 975-980.

    Google Scholar 

  11. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.NEngl JMed 1996;334:677-681.

    Google Scholar 

  12. Koopman MMW, Prandoni P, Piovella F, et al. The Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecularweight heparin administered at home. N Engl J Med 1996;334:682-687.

    Google Scholar 

  13. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection. Arch Intern Med 1998;158:1809- 1812.

    Google Scholar 

  14. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926-2932.

    Google Scholar 

  15. Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.N Engl J Med 1997;337:657-662.

    Google Scholar 

  16. Kovacs MJ, Anderson D, Morrow B, et al. Outpatient treatment of pulmonary embolism with dalteparin.Thromb Haemost 2000;83:209-211.

    Google Scholar 

  17. Comerota AJ, Thron RC, Mathias SD. Catheter-directed thrombolysis for iliofemoral deep vein thrombosis improves health-related quality of life. J Vasc Surg 2000;32:130-137.

    Google Scholar 

  18. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry. Circulation 1997;96:882-888.

    Google Scholar 

  19. Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Int J Cardiol 1998;65:S91-S93.

    Google Scholar 

  20. H$#x00E9;ron E, Lozinguez O, Emmerich J, et al. Long-term sequelae of spontaneous axillary-subclavian venous thrombosis.Ann Intern Med 1999;131:510-513.

    Google Scholar 

  21. Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation. Vasa 2001;30:195-204.

    Google Scholar 

  22. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: A randomized cross-over comparison. Lancet 2000;356:97-102.

    Google Scholar 

  23. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation.JAMA 1999;281:145-150.

    Google Scholar 

  24. Schulman S, Granqvist S, Holmstr$#x00D6;m M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398.

    Google Scholar 

  25. Ridker PM, Goldhaber SZ, Danielson E, et al. Longterm low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434.

    Google Scholar 

  26. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventionalintensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:C31-C39.

    Google Scholar 

  27. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic proximal deep venous thrombosis. N Engl J Med 2001;345:165-169.

    Google Scholar 

  28. Palareti G, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: High negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87:7-12.

    Google Scholar 

  29. Crowther MA, Douketis JD, Schnurr T, et al. Oral Vitamin K lowers the international normalized ratio more rapidly than subcutaneous Vitamin K in the treatment of warfarin-associated coagulopathy. Ann Intern Med 2002; 137:251-254.

    Google Scholar 

  30. Haire WD, Denman EA. Laboratory testing for hypercoagulable states: Use in clinical decision making. Vein Line 2001;2:3-4.

    Google Scholar 

  31. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-1138.

    Google Scholar 

  32. Lee AY, Levine MN, Baker KI, et al. Low-molecularweight heparin versus a coumarin for the prevention of recurrent thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.

    Google Scholar 

  33. Erikson BI, Bauer KA, Lassen MR, et al. The Pentasaccharide in Hip-Fracture Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304.

    Google Scholar 

  34. Turpie AGG, Gallus AS, Hoek JA. The Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.N Engl J Med 2001;344:619-625.

    Google Scholar 

  35. Bauer KA, Eriksson BI, Lassen MR, et al. The Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310.

    Google Scholar 

  36. Eriksson BI, Arfwidsson A-C, Frison L, et al. A doseranging study of the oral direct thrombin inhibitor ximelagatran and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I.Thromb Haemost 2002;87:231-237.

    Google Scholar 

  37. Heit JA, Colwell CW, Francis CW, et al. The AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after 232 Spyropoulos and Haire total knee replacement. Arch Intern Med 2001;161:2215- 2221.

    Google Scholar 

  38. Lee A, Agnelli G, Büller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001;10:74–78.

    Google Scholar 

  39. Money SR, York JW. Development of oral herapin therapy for prophylaxis and treatment of deep venous thrombosis. Cardiovasc Surg. 2001; 9: 211–218.

    Google Scholar 

  40. Evatt B. ASH Committee on Training Programs/AHOPD news on training in non-malignant hematology, "Manpower needs in non-malignant hematology" August 2001. Available at www.hematology.org/training/nonmalignant hematology.cfm

  41. Demaria AN. Peripheral vascular disease and the cardiovascular specialist. J AmColl Cardiol 1988;12:869-870.

    Google Scholar 

  42. Cooke JP, Dzau VJ. The time has come for vascular medicine. Ann Intern Med 1990;112:138-139.

    Google Scholar 

  43. Widmer LK. The time has come for vascular medicine? Angiology: A subspecialty of internal medicine and dermatology in Switzerland. Int Angiol 1991;10:162-166.

    Google Scholar 

  44. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389.

    Google Scholar 

  45. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998;158:585-593.

    Google Scholar 

  46. Goldhaber SZ, Ridker PM. Thrombosis and Thromboembolim.New York: Marcel Dekker, Inc., 2002.

    Google Scholar 

  47. Gray DR, Garabedian-Ruffalo SM, Chretien SD. Costjustification of a clinical pharmacist-managed anticoagulation clinic. Drug Intell Clin Pharm 1985;19:575-580.

    Google Scholar 

  48. Wilt VM, Gums JG, Ahmed OI, et al. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 1995;15:732-739.

    Google Scholar 

  49. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs.Arch Intern Med 1998;158:1641-1647.

    Google Scholar 

  50. Nathan DG. Careers in translational clinical research– Historical perspectives, future challenges. JAMA 2002;287:2424-2427.

    Google Scholar 

  51. Spyropoulos AC, Hurley JS, Ciesla GN, et al. Management of acute proximal deep vein thrombosis: Pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest. 2002;122:108-114.

    Google Scholar 

  52. Spyroponlos AC, Frost F, Hurley JS, et al. Costs and clinical outcomes associated with low-molecular-weightheparin versus unfractionated heparin for perioperative bridging in patients on chromic oral anticoagulant therapy. Chest. (in press).

Download references

Author information

Authors and Affiliations

  1. Clinical Thrombosis Center, Lovelace Health Systems, Albuquerque, NM, USA

    Alex C. Spyropoulos

  2. Department of Internal Medicine, Section of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA

    William Haire

Authors
  1. Alex C. Spyropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William Haire
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spyropoulos, A.C., Haire, W. The Clinical Thrombosis Center and Clinical Thrombologist: A New US Health Systems Paradigm for the Management of Venous Thromboembolic Disease. J Thromb Thrombolysis 15, 227–232 (2003). https://doi.org/10.1023/B:THRO.0000011378.16223.e4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:THRO.0000011378.16223.e4

Search

Navigation